Table 3.
Adjusted HRs of all-cause mortality associated with race (black women vs. white women)
| |
White |
Black |
Model 1a |
Model 2a,b |
||||
|---|---|---|---|---|---|---|---|---|
| Person-years | Death (No.) | Person-years | Death (No.) | HR | 95% CI | HR | 95% CI | |
|
All women |
6246 |
155 |
4471 |
180 |
1.65 |
1.32 to 2.06 |
1.42 |
1.13 to 1.78 |
| Subtypes defined by ER/PR/HER2 |
|
|
|
|
|
|
|
|
| TN |
1341 |
50 |
1381 |
66 |
1.25 |
0.85 to 1.84 |
1.12 |
0.76 to 1.66 |
| Luminal A |
3853 |
75 |
2235 |
70 |
1.75 |
1.25 to 2.46 |
1.54 |
1.09 to 2.18 |
| Luminal B |
643 |
16 |
481 |
16 |
1.74 |
0.70 to 4.31 |
1.07 |
0.32 to 3.53 |
| HER2-enriched |
408 |
14 |
375 |
28 |
2.69 |
1.06 to 6.85 |
2.41 |
0.90 to 6.40 |
| Subtypes defined by ER/PR/HER2/p53 |
|
|
|
|
|
|
|
|
| TN/p53- |
825 |
26 |
664 |
34 |
1.45 |
0.82 to 2.54 |
1.38 |
0.77 to 2.49 |
| TN/p53+ |
516 |
24 |
717 |
32 |
1.04 |
0.58 to 1.88 |
1.04 |
0.57 to 1.89 |
| Luminal A/p53- |
3262 |
55 |
1814 |
52 |
1.73 |
1.16 to 2.58 |
1.62 |
1.08 to 2.43 |
| Luminal A/p53+ |
591 |
20 |
421 |
18 |
1.45 |
0.60 to 3.54 |
0.99 |
0.37 to 2.70 |
|
Younger women (ages 35–49 yrs) |
3066 |
90 |
2248 |
95 |
1.49 |
1.10 to 2.01 |
1.27 |
0.94 to 1.73 |
| Subtypes defined by ER/PR/HER2 |
|
|
|
|
|
|
|
|
| TN |
861 |
34 |
785 |
43 |
1.36 |
0.84 to 2.18 |
1.16 |
0.71 to 1.89 |
| Luminal A |
1623 |
36 |
1069 |
28 |
1.33 |
0.79 to 2.23 |
1.20 |
0.71 to 2.03 |
| Subtypes defined by ER/PR/HER2/p53 |
|
|
|
|
|
|
|
|
| TN/p53- |
513 |
18 |
372 |
21 |
1.44 |
0.72 to 2.87 |
1.43 |
0.70 to 2.90 |
| TN/p53+ |
349 |
16 |
413 |
22 |
1.21 |
0.60 to 2.47 |
1.13 |
0.54 to 2.36 |
| Luminal A/p53- |
1329 |
28 |
792 |
17 |
1.06 |
0.56 to 2.01 |
1.05 |
0.54 to 2.02 |
| Luminal A/p53+ |
294 |
8 |
277 |
11 |
1.32 |
0.32 to 5.42 |
0.92 |
0.21 to 4.06 |
|
Older women (ages 50–64 yrs) |
3181 |
65 |
2223 |
85 |
1.89 |
1.36 to 2.62 |
1.62 |
1.17 to 2.26 |
| Subtypes defined by ER/PR/HER2 |
|
|
|
|
|
|
|
|
| TN |
480 |
16 |
596 |
23 |
1.04 |
0.54 to 2.02 |
1.07 |
0.55 to 2.11 |
| Luminal A |
2231 |
39 |
1167 |
42 |
2.21 |
1.40 to 3.47 |
1.88 |
1.18 to 2.99 |
| Subtypes defined by ER/PR/HER2/p53 |
|
|
|
|
|
|
|
|
| TN/p53- |
313 |
8 |
292 |
13 |
1.66 |
0.61 to 4.54 |
1.48 |
0.50 to 4.41 |
| TN/p53+ |
167 |
8 |
304 |
10 |
0.77 |
0.27 to 2.20 |
0.79 |
0.27 to 2.30 |
| Luminal A/p53- |
1934 |
27 |
1022 |
35 |
2.49 |
1.47 to 4.22 |
2.22 |
1.30 to 3.79 |
| Luminal A/p53+ | 297 | 12 | 144 | 7 | 1.54 | 0.48 to 4.91 | 1.44 | 0.25 to 8.11 |
HRs are from multivariable Cox proportional hazards regression models using age (in days) at diagnosis and at death or end of follow-up as the time scale and stratified by single years of age at diagnosis. aAdjusted for study site. bAdditionally adjusted for tumor stage. Abbreviations: HR, hazard ratio; CI, confidence interval. ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TN, triple negative. Note: TN = ER-/PR-/HER2-, Luminal A = ER+ or PR+ plus HER2-, Luminal B = ER+ or PR+ plus HER2+, HER2-enriched = ER-/PR-/HER2+.